Approximately 2 million Americans suffer from deep vein thrombosis (DVT) every year. Deep vein thrombosis is the formation of a blood clot in a deep vein of the body, including the internal jugular veins, the radial veins in the arms, and the femoral veins in the legs, where DVT is most common.
DVT can be painful, causing swelling, redness, and in severe cases, pulmonary embolism. This is why DVT research is so important. To help advance the treatment of DVT, specialists at St.Vincent Heart Center are participating in an NIH (National Institutes of Health) study known as the ATTRACT trial, or Acute Venous Thrombosis: Thrombous Removal with Adjunctive Catheter-Directed Thrombolysis.
The trial tests the use of catheters to dissolve blood clots that cause post thrombotic syndrome—a term used to describe the symptoms of long-term deep vein thrombosis. While current blood-thinning methods help blood to flow around clots, it does not completely remove the clot. Catheter-directed thrombolysis delivers “clot-busting” medication directly to a clot, allowing most to be completely dissolved within 24 hours. And it’s believed that removing clots can prevent post thrombotic syndrome.
Patients should always be aware of the risks for DVT. If you think participation in the ATTRACT trial may be right for you, consult with your primary care physician, and refer him or her to:
Kannan Natarajan, M.D.
Interventional Radiologist with St.Vincent Medical Group
Principal Investigator for the ATTRACT Trial at St Vincent Heart Center of Indiana